Article
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
PloS one - 26 Aug 2008
Chrisanthar Ranjan, Knappskog Stian, Løkkevik Erik, Anker Gun, Østenstad Bjørn, Lundgren Steinar, Berge Elisabet O, Risberg Terje, Mjaaland Ingvil, Maehle Lovise, Engebretsen Lars Fredrik, Lillehaug Johan Richard, Lønning Per Eystein
Abstract excerpt
BACKGROUND: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression profiles have failed to identify mechanisms causing in vivo resistance to anthracyclines. While we previously found TP53 mutations in the L2/L3 domains to be associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.